bicalutamide tablet
remedyrepack inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see us
bicalutamide 50mg tablets
a a h pharmaceuticals ltd - bicalutamide - oral tablet - 50mg
bicalutamide 50mg tablets
zentiva pharma uk ltd - bicalutamide - oral tablet - 50mg
bicalutamide 50mg tablets
viatris uk healthcare ltd - bicalutamide - oral tablet - 50mg
bicalutamide 50mg tablets
sun pharma uk ltd - bicalutamide - oral tablet - 50mg
bicalutamide 50mg tablets
de pharmaceuticals - bicalutamide - oral tablet - 50mg
bicalutamide tablet
sorres pharma inc - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents
bicalutamide teva 50 mg
teva israel ltd - bicalutamide - tablets - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.
bicalutamide inovamed 50 mg
inovamed ltd - bicalutamide - film coated tablets - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (lhrh) analog therapy or surgical castration.
dom-bicalutamide tablet
dominion pharmacal - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents